<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496182</url>
  </required_header>
  <id_info>
    <org_study_id>C34-11</org_study_id>
    <nct_id>NCT02496182</nct_id>
  </id_info>
  <brief_title>Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment</brief_title>
  <acronym>Picheon</acronym>
  <official_title>Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Medifarma, S. A. de C. V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Medifarma, S. A. de C. V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Chronic Hypersensitivity Pneumonitis (HP), is an inflammatory disease who has an
      evolution to develop progressive interstitial fibrosis, who cause the death of the patient.
      Actually HP has been treated with Prednisone and occasionally with Azathioprine, but
      unfortunately the treatment with these drugs have not an effective result to treat the
      interstitial fibrosis.

      Pirfenidone has been studied over the world for the treatment of Fibrotic diseases, with
      positive results, and due to the Pirfenidone mechanism of action has anti-inflammatory and
      anti-fibrotic properties, the investigators propose to evaluate the addition of Pirfenidone
      to the actual treatment with Prednisone and Azathioprine in the treatment of patients with
      Pulmonary Fibrosis secondary to a Chronic Hypersensitivity Pneumonitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Chronic Hypersensitivity Pneumonitis (HP), is a complex syndrome due to a exaggerated
      immune response caused by inhalation of foreign substances, such as molds, dusts, and organic
      particles, causing alveoli inflammation and in the chronic forms the disease has high rate of
      mortality, due to the big number of patients who develop progressive interstitial fibrosis
      and eventually they curse with respiratory insufficiency who cause the death of the patient.

      Pirfenidone has been studied over the world for the treatment of Idiophatic Pulmonary
      Fibrosis (IPF), disease who constitute the most aggressive of the fibrotic diseases of the
      lung. Additionally Pirfenidone has been showed potential results in the treatment of fibrotic
      diseases in other organs, as Liver, Kidney, Hearth, etc. Pirfenidone has been described as a
      modulator of the fibrotic process due to his action over TGF-beta and MMP´s and also has
      into-inflammatory actions acting over TNF-alfa and IL-1 and IL-6.

      Actually HP has been treated with Prednisone and occasionally with Azathioprine, but a high
      number of patients will develop irreversibly to a interstitial fibrosis with pulmonary
      parenchyma destruction. Unfortunately the investigators have not an effective treatment for
      this cases. Due to the positive results obtained with Pirfenidone in the treatment of IPF and
      other kind of organ fibrosis, the investigators propose to evaluate the addition of
      Pirfenidone to the treatment with Prednisone and Azathioprine in the treatment of patients
      with Pulmonary Fibrosis secondary to a Chronic Hypersensitivity Pneumonitis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>52 weeks</time_frame>
    <description>The measurement of FVC will be at 26 and 52 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Resolution Tomography</measure>
    <time_frame>52 weeks</time_frame>
    <description>Evaluation of the inflammation and fibrosis grade with the Kazerooni scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes walk distance test</measure>
    <time_frame>52 weeks</time_frame>
    <description>quantification of the walking distance at 6 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>San George Qty Score, SOBQ and EQ5D Quality Scores</measure>
    <time_frame>52 weeks</time_frame>
    <description>As a composite outcome to evaluate the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary artery systolic pressure with echocardiogram</measure>
    <time_frame>52 weeks</time_frame>
    <description>measurement of pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen desaturation in exercise</measure>
    <time_frame>52 weeks</time_frame>
    <description>Measurement of Oxygen</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alveolitis Extrinsic Allergic</condition>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Conventional treatment (Prednisone 0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Placebo tablet 2 times at day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pirfenidone 1800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 900 mg 2 times at day, starting with 600 mg at day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pirfenidone 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 600 mg 2 times at day starting with 600 mg at day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet only with the excipients of the Pirfenidone tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Excipient Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg</description>
    <arm_group_label>Pirfenidone 1800 mg</arm_group_label>
    <other_name>Kitoscell LP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg</description>
    <arm_group_label>Pirfenidone 1200 mg</arm_group_label>
    <other_name>KitosCell LP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Hypersensitivity pneumonitis with recent diagnosis confirmed by HRT with or
             without biopsy

          -  Acceptation with signed informed consent

        Exclusion Criteria:

          -  No confirmed diagnosis

          -  Patients with peptic ulcer

          -  Pregnancy or breast feeding period

          -  Clinical signs of active infection

          -  History of severe Hepatic disease

          -  History of severe Kidney disease, who requires some kind of dialysis

          -  History of inestable cardiopathy

          -  History of alcohol or drugs abuse

          -  Bronchial hyperactivity or History of asthma or EPOC

          -  Smoking habit 3 months before the starting or patient who decline suspend the smoking
             habit during the study

          -  Patient with impossibility to make spirometry or who can not walk

          -  Use of Immunosuppressants, cytotoxic agents, cytosine modulators or receptor
             antagonist, fluvoxamine or daily use of sildenafil.

          -  Patients who not accept sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pedro Pena, MD</last_name>
    <phone>+52191971972</phone>
    <email>pedropena@grupomedifarma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jarod Escobar, MD</last_name>
    <phone>+525515764477</phone>
    <email>jarodescobar@cellpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias</name>
      <address>
        <city>Mexico city</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidegger Mateos, MD</last_name>
      <phone>+5255 5487 1771</phone>
    </contact>
    <contact_backup>
      <last_name>Pedro Pena, MD</last_name>
      <phone>+5215591971972</phone>
      <email>pedropena@grupomedifarma.com</email>
    </contact_backup>
    <investigator>
      <last_name>Moises Selman Lama, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mayra Mejia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heidegger Mateo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivette Buendia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M, Cormier Y; HP Study Group. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003 Oct 15;168(8):952-8. Epub 2003 Jul 3.</citation>
    <PMID>12842854</PMID>
  </reference>
  <reference>
    <citation>Selman M. Hypersensitivity pneumonitis: a multifaceted deceiving disorder. Clin Chest Med. 2004 Sep;25(3):531-47, vi. Review.</citation>
    <PMID>15331190</PMID>
  </reference>
  <reference>
    <citation>Gaxiola M, Buendía-Roldán I, Mejía M, Carrillo G, Estrada A, Navarro MC, Rojas-Serrano J, Selman M. Morphologic diversity of chronic pigeon breeder's disease: clinical features and survival. Respir Med. 2011 Apr;105(4):608-14. doi: 10.1016/j.rmed.2010.11.026. Epub 2010 Dec 16.</citation>
    <PMID>21167698</PMID>
  </reference>
  <reference>
    <citation>Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010 Sep 1;3:16. doi: 10.1186/1755-1536-3-16.</citation>
    <PMID>20809935</PMID>
  </reference>
  <reference>
    <citation>Selman M, Pardo A, Richeldi L, Cerri S. Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2011 Jun;16(2):341-62. doi: 10.1517/14728214.2011.565049. Epub 2011 Mar 17. Review.</citation>
    <PMID>21410428</PMID>
  </reference>
  <reference>
    <citation>Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011 Jun;20(120):85-97. doi: 10.1183/09059180.00001111. Review.</citation>
    <PMID>21632796</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>July 13, 2015</last_update_submitted>
  <last_update_submitted_qc>July 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Alveolitis, Extrinsic Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

